ASCO Annual Meeting

Annual Meeting of American Society of Clinical Oncology (ASCO)

Orlando, May 29 - June 2, 2009

Roche and Genentech offered two joint analyst briefings, one on Sunday May 31 and one on Monday June 1, to cover ASCO newsflow. Several presentations were given by leading investigators/key opinion leaders as well as Roche and Genentech management.

Investor Updates

  • Roche to present major advances with targeted cancer medicines at ASCO more...
  • New form of targeted therapy offers further hope to patients with advanced HER2-positive breast cancer more...
  • Full results from first Phase III study of Avastin in adjuvant colon cancer announced more...
  • Phase III study showed patients lived longer without advanced lung cancer progressing when Tarceva was added to Avastin as first-line maintenance therapy more...
  • Herceptin landmark study (ToGA) reveals unprecedented survival benefit in HER2-positive stomach cancer more...
  • Encouraging first data on new targeted treatment for patients with melanoma – the deadliest form of skin cancer more...

More Information

Roche ASCO Planner


Roche ASCO Analyst Briefing (part 1) Sunday, 31 May 2009, 6:30pm (EDT), 0:30am (CEST) June 1st

Download MP3 file

Presentation Slides

Roche ASCO Analyst Briefing (part 2) Monday, 1 June, 2009, 6:30pm (EDT), 0:30am (CEST) June 2nd

Download MP3 file

Presentation Slides